Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study-Reference-Cited by-同舟云学术

Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study

Published:2018-07-24 Issue:8 Volume:35 Page:1153-1168
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Sarzi-Puttini Piercarlo,Filippucci Emilio,Adami Silvano,Meroni Pier Luigi,Batticciotto Alberto,Idolazzi Luca,De Lucia Orazio,Talavera Pablo,Kumke Thomas,Grassi Walter

Funder

UCB Pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-018-0751-8.pdf

Reference55 articles.

1. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.

2. McDonnell T, Ioannou Y, Rahman A. PEGylated drugs in rheumatology—why develop them and do they work? Rheumatology (Oxford). 2014;53(3):391–6.

3. Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014;28(1):15–23.